Simtriyo Is Approved but Not Yet Prescribable. Use the DEA Gap to Get Your PMHNP Practice Ready.

·

Somewhere in your schedule this week is a parent who read about Simtriyo and wants to know if their 14-year-old can switch. Maybe it’s an adult patient who quit methylphenidate because she was lying awake until 2 a.m. They saw “first new kind of ADHD drug in decades” and they want in.

Here’s what you can tell them today: not yet. The FDA approved centanafadine, sold as Simtriyo, on July 24, 2026, for ADHD in adults and children 6 and older who weigh at least 20 kg. But the drug can’t ship until the Drug Enforcement Administration assigns it a controlled substance schedule, and as of this week no scheduling action has appeared in the Federal Register. Coverage from Psychiatric Times and Understood both describe availability as “later in 2026,” contingent on DEA.

That gap is useful. It gives a PMHNP running a private practice a few weeks, maybe a couple of months, to decide who this drug is actually for, what the label requires, and whether your registration, your state rules, and your intake workflow are ready for it. Practices that use the window will have calm, well-documented first prescriptions. Practices that don’t will be improvising in the middle of a med check.

What the label actually says (and what the headlines got wrong)

Most consumer coverage called Simtriyo a “non-stimulant.” The FDA label doesn’t. It classifies centanafadine as a central nervous system stimulant, and it will be regulated as a scheduled controlled substance. That distinction matters for your prescribing workflow, your PDMP checks, and what you say to a patient who specifically asked for “something that isn’t a stimulant.”

The marketing hook is the mechanism. Centanafadine is described as a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), the first approved for ADHD. In a Psychiatric Times interview published in August, Raman Baweja, MD, of Penn State College of Medicine, framed the serotonergic piece as the real novelty and pointed to executive dysfunction and emotional dysregulation as areas where it might earn a place.

Ryan Sultan, MD, who read all seven published centanafadine trials for a Psychology Today analysis in August, offers a useful correction. Based on published binding data, centanafadine is roughly sixfold less potent at the dopamine transporter and 14-fold less potent at the serotonin transporter than at the norepinephrine transporter. At clinical doses, he argues, it behaves mostly like a norepinephrine drug, pharmacologically closer to atomoxetine than to amphetamine. Keep that in your head. It predicts most of what the trials found.

A few label details to have ready before your first prescription:

  • Starting doses. Adults start at 210 mg once daily. Adolescents 13 to 17 take 280 mg once daily. Children 6 to 12 are dosed by weight. It’s an extended-release tablet taken once a day.
  • Boxed warning. The label carries a boxed warning for suicidal ideation and behavior in pediatric patients with ADHD, specifically flagged in the 6-to-12 age group. That belongs in your consent conversation and your chart note, not buried in a handout.
  • Abuse and misuse. Despite trial data suggesting low abuse potential, the label still warns that misuse can lead to a substance use disorder. Treat it like any other controlled stimulant until the DEA tells you otherwise.
Overhead flat lay of a blank clipboard, fountain pen and a small dish of white tablets on slate

How much does it actually help?

This is the question your patients will skip past and the one you can’t. The phase 3 program covered children, adolescents, and adults. The adolescent trial, published by Ward and colleagues in the Journal of the American Academy of Child and Adolescent Psychiatry, tested two doses over six weeks. Only the higher dose beat placebo on the ADHD Rating Scale. The adult trials, reported by Adler and colleagues in the Journal of Clinical Psychopharmacology, showed both doses separating from placebo at week 6.

Sultan’s summary of effect sizes across the four positive dose arms: 0.24 to 0.40. For comparison, he cites a large network meta-analysis of adult ADHD medications that put amphetamines at 0.79, methylphenidate at 0.49, and atomoxetine at 0.45. So centanafadine sits at the low end of the non-stimulant range and roughly half of amphetamine. Cross-trial comparisons are never clean, but the direction is consistent.

There’s real good news in the data, too. In the adolescent trial, 69.1% of patients on the approved dose reached at least a 30% symptom improvement, compared with 50.3% on placebo. That’s about one additional responder for every five patients treated.

Two more caveats worth knowing before a patient quotes the brochure back to you:

“Works in week 1” is narrower than it sounds. In adolescents, the week-1 separation from placebo was entirely in inattention. Hyperactivity and impulsivity didn’t separate until week 3, and then plateaued at about half the inattention effect. In adults, two identically designed trials ran side by side. One separated at day 7. The other didn’t separate until day 28.

No head-to-head trial exists. The comparative claims you’ll hear come from indirect statistical comparisons funded by the manufacturer. One found centanafadine significantly worse than lisdexamfetamine. The comparisons against methylphenidate, atomoxetine, and viloxazine found no significant difference, which is being widely repeated as “comparable efficacy.” As Sultan points out, failing to detect a difference is not the same as showing two drugs are equivalent. Those confidence intervals were wide enough to hide a meaningful gap.

Where it genuinely fits

None of this makes the drug a dud. It makes it a tool with a specific job. The tolerability story is more convincing than the efficacy story. Sultan calls insomnia the best-documented advantage, with meaningfully fewer insomnia events than long-acting methylphenidate. Understood reported adult trial side effects in single digits: decreased appetite around 6.5%, dry mouth and nausea around 5.5% each, headache around 4.5%. In the 6-to-12 trial, decreased appetite was 5%, rash and vomiting 3% each.

Jodi Gold, MD, an adult and pediatric psychiatrist quoted by Understood, put the appeal plainly: a lot of adolescents feel stimulants help but hate how they feel on them. For those patients, a drug with less impact on sleep and appetite is a meaningful option even if the ceiling is lower.

Pulling the independent commentary together, the reasonable early candidates look like this:

  • Patients with predominantly inattentive presentations, where the week-1 signal actually lived.
  • Patients for whom insomnia is the main reason stimulants failed.
  • Patients who didn’t tolerate atomoxetine or viloxazine and want another non-amphetamine, non-methylphenidate option.

And the patients who probably shouldn’t be first in line: someone doing well on lisdexamfetamine who’s curious, a child in the 6-to-12 range with any suicide-risk history, or anyone already on multiple serotonergic agents. Ann Childress, MD, who worked on several of the trials, told Understood that clinicians should be cautious when combining it with other drugs that raise serotonin, and that patients on antidepressants or anti-anxiety medications should talk through risks and benefits with their prescriber. Read the label’s interaction section yourself before you co-prescribe with an SSRI or SNRI.

Empty modern psychiatric practice waiting room with teal armchairs in warm afternoon light

Five things to settle while the DEA decides

This is the practical part. None of it requires knowing the final schedule, and all of it will save you time later.

1. Check your DEA registration and your state’s rules by schedule

Your federal DEA registration lists the schedules you’re authorized to prescribe. If Simtriyo lands in Schedule II, that’s the same bucket as amphetamine and methylphenidate, and most PMHNPs already prescribing stimulants will be covered. If it lands in a lower schedule, the federal side is simpler. But several states layer their own limits on NP prescribing of Schedule II drugs, including collaborative agreement requirements, day-supply caps, or specific protocol language. Pull your state board’s controlled substance rules now so you can check them the day the schedule is announced.

2. Map your telehealth exposure

If a meaningful share of your ADHD panel is seen by video, remember that the DEA and HHS telemedicine flexibilities for controlled substances currently run through December 31, 2026. A new controlled stimulant arriving in the last quarter of the year, right as those flexibilities approach their end date, is exactly the kind of timing that creates a mess. Know which of your likely Simtriyo candidates you’ve seen in person, and which states they live in.

3. Expect coverage friction

Understood warned families that insurance may not cover it right away, and that’s the usual pattern for a new brand in a crowded class with generic alternatives. Expect non-formulary status, prior authorization, and step therapy requiring failure of one or more generics. Build a short PA template now: diagnosis, prior trials with dates and doses, the specific reason each failed (insomnia, appetite, cardiovascular concerns, misuse risk). Most of your candidates will have that history. Documenting it cleanly is what gets approvals.

If you run a cash-pay or membership model, the math is different but the conversation is similar. A branded drug with no generic will be expensive at the pharmacy counter, and patients should hear that from you before they get attached.

4. Write the consent language before you need it

You’ll want a consent addendum that covers the boxed warning for pediatric suicidality, the abuse and misuse warning, serotonergic interaction risk, the fact that no head-to-head data exist, and a plain statement that the expected benefit is likely smaller than a traditional stimulant in exchange for better sleep and appetite. For pediatric patients, document who was present and that the boxed warning was discussed.

5. Decide your monitoring schedule

Settle it once instead of per patient: baseline vitals and weight, PDMP check at initiation and at your usual interval, a structured rating scale at baseline and week 4 to 6, and for children and adolescents, a suicidality screen at every visit during the first months. Given that hyperactivity and impulsivity took three weeks to move in the adolescent data, don’t judge a failed trial at week 1.

Wooden footbridge over a misty creek leading toward a sunlit forest clearing at dawn

What to put on your website, and what to leave off

Patients are searching “Simtriyo” right now, and the search results are dominated by manufacturer pages and general health sites. A short, honest FAQ on your practice website can be the page that answers them. Something like: what it is, that it isn’t available yet, who might be a candidate, that it’s still a controlled stimulant, and how to request an evaluation at your practice.

Keep it factual. Don’t imply it’s better than existing medications. That claim isn’t supported. Don’t promise availability dates, and don’t use the brand name in paid ads without checking your ad platform’s healthcare and prescription drug policies first. A page that says “we’re following the DEA scheduling process and will contact existing patients when it’s prescribable” builds more trust than one that sounds like a launch announcement.

You can also use the interest as a quiet triage tool. If an existing patient asks, add a tag in your EHR. When the schedule posts, you’ll have a ready list of people to review, and you can prioritize the ones with documented insomnia or non-stimulant intolerance rather than whoever calls first.

The bigger lesson for your practice

Sultan closes his analysis with four questions worth asking about any new psychiatric drug: Was it compared with anything besides placebo? Who funded the comparisons? Does the onset or benefit claim describe all patients, or the best subgroup? And is the tolerability advantage a separate virtue, or the expected trade-off of a milder drug?

Those questions are a good habit for a solo prescriber who doesn’t have a P&T committee reviewing new agents. In private practice, you are the formulary. Every new launch will arrive with patient demand ahead of the evidence, and the practices that do well are the ones that have a routine for sorting it out before the first request lands.

Simtriyo will probably earn a modest, real place in ADHD care. Your job right now is making sure that when it becomes prescribable, your registration, your consent forms, your PA templates, and your patient list are already waiting.

If you want a practice website that answers patient questions like this before they reach your inbox, and positions you as the clinician who explains new treatments honestly, see how PMHNP Website builds sites for psychiatric nurse practitioners.